Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Searching the Web
National Vector Borne Disease Control Programme India chikungunya NVBDCP
Finding Sources
I now have all the information needed from authoritative textbook sources. Let me compile the complete answer.
Q.3 - Detailed Answer
a. Most Probable Diagnosis (2 marks)
Chikungunya Fever
Reasoning:
| Feature in the case | Fits Chikungunya |
|---|---|
| High fever (>39°C) | Yes - acute onset high fever is hallmark |
| Severe joint pain (most prominent) | Yes - polyarthralgia/arthritis is the defining feature (name means "to become contorted") |
| Rash | Yes - maculopapular rash on trunk and extremities |
| Fatigue | Yes - common systemic symptom |
| Stagnant water / poor sanitation | Yes - breeding ground for Aedes mosquitoes |
| Multiple neighbors affected (cluster) | Yes - epidemic/outbreak pattern typical |
| Rural village setting | Yes - common in India's rural endemic zones |
The severe joint pain disproportionate to other symptoms is the classic distinguishing feature of Chikungunya over Dengue. Fever is typically >39°C and can be biphasic. Rash usually appears after fever onset and typically involves the trunk and extremities.
- Red Book 2021, p. 449
b. National Health Program (2 marks)
National Vector Borne Disease Control Programme (NVBDCP)
- The NVBDCP is India's nodal national program under the Ministry of Health & Family Welfare that addresses six vector-borne diseases: Malaria, Dengue, Chikungunya, Kala-azar, Lymphatic Filariasis, and Japanese Encephalitis.
- It provides surveillance, outbreak response, vector control strategies, and public health education for Chikungunya at the national level.
- At state and district levels, it coordinates with the State Vector Borne Disease Control Societies.
- The program also includes the National Health Mission (NHM) framework for rural community-level delivery.
c. Steps in Confirmation of Diagnosis (5 marks)
Diagnosis is based on a combination of clinical, epidemiological, and laboratory criteria.
Step 1 - Clinical Diagnosis (Syndromic Surveillance)
- Acute onset of high fever (>39°C)
- Severe bilateral, symmetric polyarthralgia/arthritis (hands, feet, large joints)
- Maculopapular rash (trunk and extremities)
- Supporting features: headache, myalgia, fatigue, conjunctivitis, nausea
Step 2 - Epidemiological Criteria
- Travel to or residence in endemic/epidemic area
- Temporal clustering (neighbors with similar symptoms = outbreak indicator)
- Exposure history: stagnant water, Aedes mosquito breeding sites nearby
Step 3 - Laboratory Confirmation
| Timing | Test | Result |
|---|---|---|
| Days 1-7 (acute phase) | RT-PCR (serum) - detects viral RNA | Positive = confirms acute infection |
| Day 5 onwards | IgM ELISA (serology) | IgM positive = recent/active infection |
| Day 10+ / Convalescent | IgG ELISA / Plaque Reduction Neutralization Test (PRNT) | Fourfold rise in IgG titre confirms infection |
| Any stage | NS1 antigen test (used mainly for Dengue, not primary for CHIKV) | - |
Key points:
- RT-PCR is the test of choice in the first week (viremic phase)
- IgM antibodies develop toward the end of week 1 and persist for 30-90 days
- PRNT (Plaque Reduction Neutralization Test) is the gold standard serological test and can distinguish cross-reacting antibodies from Mayaro and o'nyong nyong viruses
- Supportive labs: lymphopenia, thrombocytopenia, elevated liver enzymes, elevated creatinine
Red Book 2021, p. 450-451
d. Management of the Case and Community-Level Problem (6 marks)
Individual Case Management
There is no specific antiviral therapy for Chikungunya. Treatment is supportive:
| Component | Details |
|---|---|
| Rest | Bed rest during acute febrile phase |
| Fluids | Adequate oral hydration; IV fluids if unable to tolerate orally |
| Antipyretics | Paracetamol (acetaminophen) is the drug of choice for fever and joint pain |
| Avoid NSAIDs initially | Until Dengue is excluded (NSAIDs increase hemorrhagic risk in Dengue) |
| NSAIDs / Corticosteroids | For persistent joint pain after Dengue is ruled out |
| Physiotherapy | For patients with prolonged arthritis |
| Severe/refractory arthritis | Methotrexate or hydroxychloroquine have been used |
| Isolate from mosquitoes | Symptomatic patients must be kept under mosquito nets to prevent further transmission |
Red Book 2021, p. 451
Community-Level Management
A. Vector Control (primary strategy):
- Source reduction: Drain, empty, or cover all stagnant water collections (pots, coolers, tyres, flowerpots, rooftop tanks)
- Larviciding: Apply Temephos (Abate) in water containers that cannot be drained
- Adulticiding: Indoor Residual Spraying (IRS) and space spraying (fogging) with pyrethroid insecticides in affected areas
- Biological control: Introduce Gambusia fish or Bacillus thuringiensis israelensis (Bti) in large water bodies
B. Personal Protection:
- Insect repellents (DEET-based)
- Long-sleeved clothing during peak mosquito activity (dawn and dusk)
- Window and door screens; use of bed nets
- Limit outdoor exposure during peak Aedes feeding hours
C. Surveillance and Outbreak Response:
- Active case detection - house-to-house surveys in the affected village
- Mandatory reporting to the local health authority (NVBDCP/state health department)
- Line listing of cases, establishing case definitions, epidemic curve mapping
- Blood samples from 5-10% of suspected cases for laboratory confirmation
D. Health Education (IEC - Information, Education, Communication):
- Educate the community on Aedes mosquito breeding habits (clean water containers)
- Explain "no medication" for the virus - early reporting is key
- Community involvement in source reduction drives (Shramadan/cleanup campaigns)
E. Sanitation Improvement (long-term):
- Improvement of water supply and sewage systems in the village
- Regular municipal cleaning of open drains
- Engaging Panchayati Raj institutions (local governance) for sustained action
F. Vulnerable population protection:
- Special attention to neonates, elderly (>65 years), and those with diabetes, hypertension, cardiovascular disease (higher risk of severe disease)
Summary Table:
| Sub-question | Answer |
|---|---|
| a. Diagnosis | Chikungunya Fever |
| b. National Program | NVBDCP (National Vector Borne Disease Control Programme) |
| c. Confirmation steps | Clinical + Epidemiological + RT-PCR (days 1-7) / IgM ELISA (day 5+) / PRNT |
| d. Management | Supportive care (paracetamol, fluids, rest) + Vector control + Active surveillance + IEC |
This is a shared conversation. Sign in to Orris to start your own chat.